Collection |
Collections
-
-
Focus |
Cancer Cell Therapy
Cancer cell therapy has become one of the most promising approaches for cancer treatment. In recent years, progress in the underlying science, clinical application and manufacturing of cell therapies has accelerated dramatically.
Image: Susanne Harris -
Collection |
Coronavirus
To support urgent research to combat the ongoing outbreak of COVID-19, caused by the novel coronavirus SARS-CoV-2, the editorial teams at Nature Research have curated a collection of relevant articles.
-
Collection |
The complement system as a therapeutic target
The complement system has a key role in the innate immune system, and its dysregulation is involved in a wide range of diseases.
-
Collection |
Nature Collection on Cell Therapy
Cell therapy is becoming established as a modality that has the potential to substantially improve the treatment of a wide range of diseases.
-
Collection |
Overcoming challenges in rare genetic diseases
Rare genetic diseases affect more than 300 million people worldwide, so collectively are a major health burden.
Image: Artvile/Getty images -
Collection |
Genetic and epigenetic insights into autoimmunity
Autoimmunity is an underlying cause of many diseases. This collection of Research, Reviews and News articles from several Nature journals covers the latest advances in genetic and epigenetic research into autoimmunity and autoimmune diseases.
Image: Susanne Harris -
-
Collection |
Cancer immunotherapy
Cancer immunotherapy, which encompasses a variety of approaches that mobilise the immune system to seek out and kill cancer cells, is showing substantial potential to transform the treatment of cancer. Articles in this collection highlight the progress being made with several of the most promising immunotherapy approaches and discuss key issues for maximizing their benefits, such as how immunotherapies may be rationally combined with each other or with traditional anticancer drugs.
-
Series |
Cancer immunotherapy
A special series of articles discussing the opportunities and challenges for cancer immunotherapy.
-
Focus |
US drug development consortia
Launched a decade ago, the US Food and Drug Administration's Critical Path Initiative has helped catalyse the formation of many consortia focused on drug development challenges. In this Focus, representatives from some of the major stakeholder groups and consortia describe their roles, summarize progress so far and provide their perspectives on the opportunities, challenges and lessons learned for biomedical consortia in general.
-
Collection |
Ten years in drug discovery
To mark the tenth anniversary of Nature Reviews Drug Discovery, this collection brings together data on key indicators for the field over the past decade, as well as a selection of some of the most highly cited and downloaded articles published in the journal from each of the last ten years.
Gene therapy for rare diseases
RNA-based therapies
